Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

NCT06847724 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Sclerosis

Interventions

BIOLOGICAL: CYB704
BIOLOGICAL: Ocrevus-EU
BIOLOGICAL: Ocrevus-US

Sponsor

Sandoz